- Conditions
- Abdominal Wall, Hernia, Herniorrhaphy, Physical Therapy Modalities, Postoperative Period, Ventral Hernia
- Interventions
- Post-operative Precautions, Supervised Physical Therapy
- Other
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2113–2136
of 2,136
matching trials from the local directory fallback.
- Conditions
- Multiple Sclerosis, Radiologically Isolated Syndrome
- Interventions
- Observational
- Other
- Lead sponsor
- Centre Hospitalier Universitaire de Nīmes
- Other
- Eligibility
- Not listed
- Enrollment
- 320 participants
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Breast Cancer Metastatic, HER2 + Breast Cancer, Hormone Receptor-Positive Breast Cancer, Locally Advanced Breast Cancer (LABC), Malignant Neoplasm of Breast, Triple Negative Breast Cancer (TNBC)
- Interventions
- Two Component Product CLBR001 + ABBV-461
- Biological
- Lead sponsor
- Calibr, a division of Scripps Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 5
- States / cities
- Augusta, Georgia • Indianapolis, Indiana • Buffalo, New York + 2 more
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Pancreatic Ductal, Colorectal Neoplasms
- Interventions
- Bevacizumab, Carboplatin, Cetuximab, Cisplatin, Fluorouracil, Gemcitabine, Leucovorin, Nab-paclitaxel, Oxaliplatin, PF-07284892, PF-07985045, Paclitaxel, Pembrolizumab, Sasanlimab, pemetrexed
- Combination Product · Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 12
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 6 more
- Conditions
- EGFR Exon 19 Deletion Mutation, Lung Cancer - Non Small Cell
- Interventions
- Gene sequencing, blood draw
- Other
- Lead sponsor
- Our Lady of the Lake Hospital
- Other
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Falls with Injuries
- Interventions
- Observation
- Other
- Lead sponsor
- Methodist Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Carcinoma, Small Cell Lung
- Interventions
- Cisplatin/carboplatin plus etoposide, RRx-001 + eLOOP Device
- Drug
- Lead sponsor
- EpicentRx, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 292 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Westwood, Kansas
- Conditions
- Ankle Fracture (bimalleolar Equivalent, Bimalleolar, or Trimalleolar), Calcaneus Fractures, Clavicle Fractures, Distal Femur Fracture, Distal Humerus Fractures (intra or Extra-articular), Distal Radius Fractures, Elbow Fractures Involving a Combination of Fractures of the Radius and Uln, Femoral Neck Fractures, Femoral Shaft Fracture, Forearm Fractures (both Bone Forearm Fractures, Isolated Ulnar Shaft, Isolated Radial Shaft), Humeral Shaft Fractures, Intertrochanteric Fractures, Isolated or Multiple Metatarsal Fractures, Lisfranc Injuries, Olecranon Fractures, Patella Fracture, Phalanx Fractures of the Foot, Single or Multiple, Proximal Humerus Fractures, Radial Head or Neck Fractures, Talar Head, Neck, Body, or Process Fractures, Tibial Pilon Fracture, Tibial Shaft Fracture with or Without Associated Fibula Fracture
- Interventions
- Opioid-free pain treatment
- Other
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Falls
- Interventions
- FallScape for Persons with Alzheimer's disease or a related Dementia (FS-D)
- Behavioral
- Lead sponsor
- Brookside Research & Development Company
- Industry
- Eligibility
- 21 Years to 99 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Coupeville, Washington
- Conditions
- Advanced Non Small Cell Lung Cancer
- Interventions
- [18F]F-AraG
- Drug
- Lead sponsor
- CellSight Technologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Bladder Urothelial Cancer, Breast Cancer, Cervical Cancer, Cholangiocarcinoma, Colorectal Carcinoma, Endocervical Cancer, Esophageal Cancer, Gastric Cancer, Melanoma, Mesothelioma, Non-small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
- Interventions
- NGM831, NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®), NGM831 plus pembrolizumab (KEYTRUDA®)
- Drug
- Lead sponsor
- NGM Biopharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 9
- States / cities
- Gilbert, Arizona • Los Angeles, California • Sarasota, Florida + 6 more
- Conditions
- Breast Cancer, Cervical Cancer, Cholangiocarcinoma, Colorectal Cancer, Endocervical Cancer, Esophageal Cancer, Gastric Cancer, Glioblastoma, Melanoma, Mesothelioma, Non Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Renal Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
- Interventions
- NGM707, NGM707 plus pembrolizumab (KEYTRUDA®)
- Drug
- Lead sponsor
- NGM Biopharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 179 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Newport Beach, California • Santa Monica, California + 15 more
- Conditions
- BRAF V600E Negative, KRAS Gene Mutation Negative, Locally Advanced Unresectable Colorectal Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, NRAS Gene Mutation Negative, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
- Interventions
- Cetuximab, Irinotecan, Panitumumab, Regorafenib
- Biological · Drug
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 15
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 12 more
- Conditions
- All
- Interventions
- Not listed
- Lead sponsor
- Baseline Study LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2024
- U.S. locations
- 5
- States / cities
- South San Francisco, California • Stanford, California • Westlake Village, California + 2 more
- Conditions
- Metastatic Small Intestinal Adenocarcinoma, Recurrent Small Intestinal Carcinoma, Unresectable Small Intestinal Carcinoma
- Interventions
- Laboratory Biomarker Analysis, Pembrolizumab
- Other · Biological
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Washington D.C., District of Columbia + 5 more
- Conditions
- Endodontically Treated Teeth, Pain, Postoperative, Root Canal Infection
- Interventions
- Conventional Protocol, GentleWave
- Other
- Lead sponsor
- University of Salamanca
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Manhattan, New York
- Conditions
- Melanoma, Merkel Cell Carcinoma, Unspecified, Non Small Cell Lung Cancer, Renal Cell Carcinoma
- Interventions
- zirconium Zr 89 crefmirlimab berdoxam
- Biological
- Lead sponsor
- ImaginAb, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 6
- States / cities
- Little Rock, Arkansas • Duarte, California • Santa Monica, California + 3 more
- Conditions
- Advanced Solid Malignant Tumor, Small Cell Lung Cancer
- Interventions
- Chiauranib
- Drug
- Lead sponsor
- Chipscreen Biosciences, Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 11
- States / cities
- Encinitas, California • Fullerton, California • Atlanta, Georgia + 8 more
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Chronic Myeloid Leukemia (CML), Juvenile Myelomonocytic Leukemia (JMML), Lymphoma (Hodgkin's and Non-Hodgkin's), Myelodysplastic Syndrome (MDS)
- Interventions
- Alemtuzumab, Busulfan, CliniMACS CD34+ Reagent System, Cyclophosphamide, Fludarabine, Melphalan, Methylprednisolone, Tacrolimus, Thiotepa
- Drug · Device
- Lead sponsor
- Diane George
- Other
- Eligibility
- Up to 22 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- ALS, Age-Related Macular Degeneration, Allergies, Alopecia Areata, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, COPD, Cancer, Celiac Disease, Cirrhosis, Crohn Disease, Cystic Fibrosis, DMD, Diabetes, Dravet Syndrome, Fibromyalgia, Graves Disease, Heart Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Kidney Diseases, Leukemia, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Parkinson Disease, Pemphigus Vulgaris, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Thyroid Diseases, Ulcerative Colitis, Vasculitis, Vitiligo
- Interventions
- Specimen sample
- Diagnostic Test
- Lead sponsor
- Sanguine Biosciences
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
- Conditions
- Colorectal Cancer, Epithelial Ovarian Cancer, Gastric Cancer, Hepatocellular Carcinoma, Malignant Melanoma, Non-small Cell Lung Cancer, Osteosarcoma, Solid Tumor, Adult, Triple Negative Breast Cancer
- Interventions
- CRX100 suspension for infusion, Cyclophosphamide, Fludarabine
- Biological · Combination Product
- Lead sponsor
- BioEclipse Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • La Jolla, California • Stanford, California
- Conditions
- Health Behavior, Health Care Utilization, Sexually Transmitted Infections, Unprotected Sex
- Interventions
- SafeSpace General Health, SafeSpace Sexual Health
- Behavioral
- Lead sponsor
- Child Trends
- Other
- Eligibility
- 14 Years to 18 Years · Female only
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Cetuximab, Osimertinib, Tucatinib
- Biological · Drug
- Lead sponsor
- Jonathan Riess
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Liver Metastases, Non-small Cell Lung Cancer
- Interventions
- Liver SBRT, Pembrolizumab
- Radiation · Drug
- Lead sponsor
- VA Ann Arbor Healthcare System
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan